Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)
Yuhan Corporation
Yuhan Corporation
Novartis
Fujian Cancer Hospital
Wake Forest University Health Sciences
Peking University Cancer Hospital & Institute
First People's Hospital of Hangzhou
Shanghai Chest Hospital
First People's Hospital of Hangzhou
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Massachusetts General Hospital
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)
National Cancer Center, Korea
Swiss Cancer Institute
National Cancer Institute (NCI)